Multiple-dose pharmacokinetics of lomefloxacin: Rationale for once-a-day dosing (Q54272085)

27 May 2018

title

Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1316066

12 September 2022

Multiple-dose pharmacokinetics of lomefloxacin: Rationale for once-a-day dosing (English)

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

4 December 2023

1 reference

T. G. Mant

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1316066

12 September 2022

language of work or name

English

0 references

publication date

1 April 1992

1 reference

27 May 2018

6 April 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1316066

full work available at URL

12 September 2022

https://api.elsevier.com/content/article/PII:000293439290304T?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

https://api.elsevier.com/content/article/PII:000293439290304T?httpAccept=text/plain

4 December 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

American Journal of Medicine

4 December 2023

published in

1 reference

27 May 2018

volume

92

1 reference

27 May 2018

issue

4A

1 reference

27 May 2018

page(s)

26S-32S

1 reference

27 May 2018

In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses

4 December 2023

2

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Lack of interaction between lomefloxacin and caffeine in normal volunteers

4 December 2023

3

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa

4 December 2023

5

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Comparative in vitro activity of lomefloxacin, a difluoro-quinolone

4 December 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses

4 December 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Pharmacokinetics and safety of single oral doses of lomefloxacin

4 December 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days

4 December 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Comparative pharmacokinetics of new quinolones.

4 December 2023

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

Pharmacokinetics of temafloxacin in humans after single oral doses

4 December 2023

12

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90304-T

4 December 2023

Identifiers

1 reference

27 May 2018

1 reference

27 May 2018